Trading

Insider Trading Claims In Sanofi-Bioverativ Suit Move Forward

By Leslie A. Pappas (June 2, 2022, 9:49 PM EDT) — Former Bioverativ Inc. board member Alexander J. Denner and the activist hedge fund he controlled must face insider trading claims in a Delaware Chancery Court lawsuit alleging an unfair deal process behind the company’s $11.6 billion sale to Sanofi in 2018.

In a 50-page opinion Thursday denying dismissal of the claims, Vice Chancellor J. Travis Laster said that at this stage of the litigation it was “reasonable to infer” that Denner acted on material information when he caused Sarissa Capital Management LP to buy more than a million shares of company stock more than six months before deal.

“Denner stood to make…

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.